List of publications

  • Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG, Shultz LD, Mönkkönen J, Rédini F, Heymann D. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 2010 Dec 15;70(24):10329-39.  - (MNT team: INSERM UMR 957 - Nantes)
  • Bodet L, Ménoret E, Descamps G, Pellat-Deceunynck C, Bataille R, Le Gouill S, Moreau P, Amiot M, Gomez-Bougie P. BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma. Br J Cancer. 2010 Dec 7;103(12):1808-14. - in connection with the axis - (MNT team: INSERM UMR892/ CNRS U6299 Eq.10 - Nantes)
  • Pangault C, Amé-Thomas P, Ruminy P, Rossille D, Caron G, Baia M, De Vos J, Roussel M, Monvoisin C, Lamy T, Tilly H, Gaulard P, Tarte K, Fest T. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia. 2010 Dec;24(12):2080-9. (MNT Team: INSERM UMR 917 – Rennes)
  • Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res. 2010 Oct 1;70(19):7610-9. - (MNT team: INSERM UMR 957 - Nantes)
  • Bielawska-Pohl, A., Blesson, S., Benlalam, H., Trenado, A., Opolon, P., Bawa, O., Rouffiac, V., Dus, D., Kieda, C. & Chouaib, S. The antiangiogenic activtivity of IL-12 is increased in iNOS-/- mice and involves NK cells. J Mol Med (Berl). 2010 Aug;88(8):775-84. - (MNT Team: CNRS UPR4301 CBM- Orléans)
  • Ruiz Velasco C, Colliec-Jouault S, Redini F, Heymann D, Padrines M.Proteoglycans on bone tumor development. Drug Discov Today. 2010 Jul;15(13-14):553-60. - (MNT team: INSERM UMR 957 - Nantes)
  • Rousseau J, Escriou V, Parrot P, Picarda G, Charrier C, Scherman D, Heymann D, Rédini F, Trichet V. Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther. 2010 Jun;17(6):387-97. - (MNT team: INSERM UMR 957 - Nantes)
  • Perrot P, Rousseau J, Bouffaut A-L, Rédini F, Cassagnau E, Deschaseaux F, Heymann M-F, Heymann D, Duteille F, Trichet V, Gouin F. Safety concern between autologous fat graft, mesenchymal stem cells and osteosarcoma relapse. PLoS One. 2010 Jun 8;5(6):e10999. - (MNT team: INSERM UMR 957 - Nantes)
  • Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, Gouin F , Duplomb L, Heymann D. Interleukin-34 is expressed by giant cell tumour of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol. 2010 May;221(1):77-86. - (MNT team: INSERM UMR 957 - Nantes)
  • Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F. Preclinical evidence of using TRAIL in Ewing's sarcoma therapy: TRAIL inhibits tumor growth, prevents osteolysis and increases animal survival. Clin Cancer Res. 2010 Apr 15;16(8):2363-74. - (MNT team: INSERM UMR 957 - Nantes)
  • Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F. Tumor bone microenvironment regulates osteoprotegerin anti- or pro-tumoral activity depending on the local receptor activator of nuclear factor kB ligand/TNF related apoptosis inducing ligand balance and the presence of proteoglycans. Biochim Biophys Acta. 2010 Jan;1805(1):17-24. - (MNT team: INSERM UMR 957 - Nantes)
  • Rezvani HR, Mahfouf W, Ali N, Chemin C, Ged C, Kim AL, de Verneuil H, Taïeb A, Bickers DR, Mazurier F. (2010) Hypoxia-inducible factor-1alpha regulates the expression of nucleotide excision repair proteins in keratinocytes. Nucleic Acids Res. 2010 Jan;38(3):797-809. - (MNT team: CNRS UMR 7292 LNOx - Tours)
  • Duverger E., Lamerant-Fayel N., Frison N. & Monsigny M. Carbohydrate-lectin interactions assayed by SPR. Methods Mol Biol. 2010;627:157-78
  • Chouaib, S., Kieda, C., Benlalam, H., Noman, M.Z., Mami-Chouaib,F. & Rüegg,C. Endothelial cells as key determinants of the tumor microenvironment : interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol. 2010;30(6):529-45. - (MNT Team: CNRS UPR4301 CBM - Orléans)